MAB858-4
Anti-RSV Antibody, blend, clones 133-1H, 131-2G, and 130-12H
ascites fluid, Chemicon®, from mouse
Synonym(e):
RSV
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Größe auswählen
100 μL
CHF 843.00
Alle Fotos(1)
Größe auswählen
Ansicht ändern
100 μL
CHF 843.00
About This Item
UNSPSC-Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Empfohlene Produkte
Biologische Quelle
mouse
Qualitätsniveau
Antikörperform
ascites fluid
Antikörper-Produkttyp
primary antibodies
Klon
130-12H, monoclonal
131-2G, monoclonal
133-1H, monoclonal
Speziesreaktivität
human
Hersteller/Markenname
Chemicon®
Methode(n)
ELISA: suitable
immunofluorescence: suitable
Isotyp
IgG
Versandbedingung
wet ice
Allgemeine Beschreibung
RSV is a labile paramyxovirus that produces a characteristic fusion of human cells in tissue culture--the syncytial effect. Two subtypes, A and B, have been identified. Subtype B are characterized as the asymptomatic strains of the virus. The more severe clinical illnesses involve Subtype A strains.
Spezifität
Blend of all RSV specifications of MAB858-1, 2 and 3. Recognizes the fusion, G, and nuclear protein of both A and B strains.
Immunogen
A2
Anwendung
Research Category
Infektionskrankheiten
Infektionskrankheiten
Research Sub Category
Virale Infektionskrankheiten
Virale Infektionskrankheiten
Anti-RSV Antibody, blend, clones 133-1H, 131-2G & 130-12H is an antibody against Respiratory Syncytial Virus for use in IF, ELISA.
ELISA at 1:800+
Indirect Immunofluorescence at 1:100-200+ (fresh frozen tissue sections)
Final working dilutions must be determined by end user.
Indirect Immunofluorescence at 1:100-200+ (fresh frozen tissue sections)
Final working dilutions must be determined by end user.
Physikalische Form
Unpurified
Liquid ascites fluid.
Lagerung und Haltbarkeit
Maintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Hinweis zur Analyse
Control
RSV Control Slides, Catalogue Number 5012-5
RSV Control Slides, Catalogue Number 5012-5
Sonstige Hinweise
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Rechtliche Hinweise
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Haftungsausschluss
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Sie haben nicht das passende Produkt gefunden?
Probieren Sie unser Produkt-Auswahlhilfe. aus.
Lagerklassenschlüssel
12 - Non Combustible Liquids
WGK
nwg
Flammpunkt (°F)
Not applicable
Flammpunkt (°C)
Not applicable
Analysenzertifikate (COA)
Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Tiina Talts et al.
Microbiology spectrum, 12(4), e0306723-e0306723 (2024-02-27)
Prevention of respiratory syncytial virus (RSV) infection is now a global health priority, with a long-acting monoclonal antibody and two RSV vaccines recently licenced for clinical use. Most licenced and candidate interventions target the RSV fusion (RSV-F) protein. New interventions
John P DeVincenzo et al.
The Journal of infectious diseases, 190(5), 975-978 (2004-08-06)
Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a humanized anti-RSV monoclonal antibody, has been used extensively since 1998 to prevent severe RSV
Talita Bianca Gagliardi et al.
Intervirology, 60(1-2), 56-60 (2017-09-05)
Syncytia formation is the hallmark of the cytopathic effect caused by human respiratory syncytial virus (HRSV), which is the most important viral respiratory pathogen in children. This article reports methodological improvements in primary HRSV isolation and the importance of syncytia
Ziyin Wang et al.
Mucosal immunology, 17(2), 272-287 (2024-02-22)
Respiratory viral infections remain a major cause of hospitalization and death worldwide. Patients with respiratory infections often lose weight. While acute weight loss is speculated to be a tolerance mechanism to limit pathogen growth, severe weight loss following infection can
Hayat Caidi et al.
Methods in molecular biology (Clifton, N.J.), 1442, 13-32 (2016-07-29)
Defective interfering viral particles have been reported as important determinants of the course of viral infection, and they can markedly temper the virulence of the infection. Here, we describe a simple method, based on limiting dilution, for the removal of
Active Filters
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.
